Infectious Diseases Archive — Page 6 of 13
-
May 22, 2024
Rising syphilis cases prompt more testing during pregnancy
When found and treated early with antibiotics, syphilis is curable. Untreated syphilis can cause deafness, blindness and irreversible heart and brain damage. -
May 8, 2024
Supercomputing redesign of a COVID monoclonal antibody
The approach, which combines high-performance computing, simulation, machine learning and experimental validation, will help keep antibody drugs up to date in the future against highly variable viruses. -
April 29, 2024
New tool helps identify babies at high risk for RSV
A new tool to identify infants most at risk for severe respiratory syncytial virus (RSV) illness could aid pediatricians in prioritizing children under 1 to receive a preventive medication before RSV season (October-April). -
April 4, 2024
Tick bites and alpha-gal syndrome focus of $3.5M research grant
Vanderbilt's Scott Smith, MD, PhD, has been awarded a five-year, $3.5 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to study the human immune response to tick bites and its role in preventing tick-borne illnesses. -
April 3, 2024
Talbot leads US immunization committee
Infectious diseases researcher H. Keipp Talbot, MD, MPH, has been appointed chair of the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention. -
March 28, 2024
VUMC team discovers antibodies that may prevent severe respiratory illness
Using a technique developed at Vanderbilt University Medical Center, researchers identified antibodies that are excellent leads as potential therapies for human parainfluenza virus 3, a leading cause of acute and potentially fatal respiratory illness. -
March 15, 2024
Emerging Infections Program extends, expands disease surveillance research with new grant from the CDC
The Tennessee Emerging Infections Program has been awarded a new five-year grant from the Centers for Disease Control and Prevention to continue infectious disease surveillance research that has been conducted since 1999, and has expanded to include COVID, Mpox and HPV surveillance into oropharyngeal cancers.